Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? (Q37928232)

25 August 2017

1 reference

title

Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? (English)

1 reference

25 August 2017

0 references

J T Ribeiro

1

1 reference

25 August 2017

L T Macedo

2

1 reference

25 August 2017

G Curigliano

3

1 reference

25 August 2017

L Fumagalli

4

1 reference

25 August 2017

M Locatelli

5

1 reference

25 August 2017

M Dalton

6

1 reference

25 August 2017

A Quintela

7

1 reference

25 August 2017

J B C Carvalheira

8

1 reference

25 August 2017

S Manunta

9

1 reference

25 August 2017

L Mazzarella

10

1 reference

25 August 2017

J Brollo

11

1 reference

25 August 2017

A Goldhirsch

12

1 reference

25 August 2017

publication date

6 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

23

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

547-555

1 reference

Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Preclinical evaluation of new taxoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Peripheral neuropathy induced by microtubule-stabilizing agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR382

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.49.560

Identifiers

DOI

10.1093/ANNONC/MDR382

1 reference

25 August 2017

1 reference